Glenmark's US facility to go onstream with nod for anti-malaria drug

Market size of drug is $40 mn. Having a manufacturing footprint in the US is part of company's game plan to mitigate regulatory risk

Glenmark Pharmaceuticals' maiden US manufacturing site in Monroe, North Carolina received its first product approval from the US drug regulator -- an anti-malarial drug that enjoys a market size of around $40 million in the US. Having a manufacturing footprint in the US, is part of the company's game plan to mitigate regulatory risk.

The product, innovated by GlaxoSmithKline, is already manufactured by Glenmark in India. US Food and Drug Administration (USFDA) is a supplemental approval for Atovaquone and Proguanil Hydrochloride tablets or generic Malarone. People from the US visiting emerging countries use the drug as a preventive against malaria.

This would